Rebekah Lee
Adult Health · Dulles, VANPI 1366077604
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,628 of the $9,021 with a category attached, or 84.6%. It is spread thinly across 30 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,371, more than ten times the $123 reported in 2021. Among adult health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 340 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Inspire Medical Systems, Inc.$2K
- GSK$734
- Regeneron Healthcare Solutions, Inc.$675
- Harmony Biosciences LLC$456
- Grifols USA, LLC$449
- plus $3K from 24 others
What the payments were for
- Consulting fees$3504%
- Travel & lodging$90010%
- Food & beverage$7,62885%
- Education$1422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $2,029 |
| Inspire Medical Systems, Inc. | 22 | $1,504 |
| GSK | 39 | $734 |
| Regeneron Healthcare Solutions, Inc. | 31 | $675 |
| Harmony Biosciences LLC | 21 | $456 |
| Grifols USA, LLC | 23 | $449 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $386 |
| Jazz Pharmaceuticals Inc. | 11 | $370 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $320 |
| Sanofi | 13 | $312 |
| Amgen | 14 | $297 |
| Mylan Specialty L.p. | 13 | $262 |
| Electromed, Inc. | 9 | $158 |
| Insmed, Inc. | 5 | $128 |
| Axsome Therapeutics, Inc. | 5 | $122 |
| United Therapeutics Corporation | 5 | $111 |
| Mallinckrodt Hospital Products Inc. | 4 | $98 |
| 3b Medical, Inc. | 2 | $95 |
| Boehringer Ingelheim | 4 | $83 |
| Viatris Specialty LLC | 4 | $81 |
| ZOLL Respicardia, Inc. | 3 | $81 |
| Verona Pharma, Inc. | 3 | $64 |
| Philips North America LLC | 3 | $49 |
| Vifor Pharma, Inc. | 1 | $34 |
| Phadia US Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $20 |
| Pulmonx Corporation | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,021 in reported general payments places this provider in the 95th percentile of 368 adult health providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 43 | $542,354 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 318 | $277,959 |
| TezspireTezepelumab-Ekko | 13 | $58,243 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $50,303 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $39,611 |
| Spiriva RespimatTiotropium Bromide | 25 | $20,097 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $13,645 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $13,256 |
| Pirfenidone | 15 | $10,654 |
| DuleraMometasone/Formoterol | 23 | $8,724 |
| Arnuity ElliptaFluticasone Furoate | 29 | $8,263 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $7,851 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $4,462 |
| Tiotropium Bromide | 13 | $4,212 |
| Wixela InhubFluticasone Propion/Salmeterol | 44 | $3,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $83 | $570,30279 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $734 | $339,090451 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $2,029 | $108,54572 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 368 adult health providers in Virginia.
Other adult health in Dulles
- Christine KesslerFort Belvoir$107K
- Denise BruenCharlottesville$45K
- Theresa Harrington StukusFairfax$40K
- Chelsea KoskovichFredericksburg$34K
- Brittany BrownLynchburg$14K
- Colleen DieringVirginia Beach$13K
- Veronica HughesRichmond$12K
- Nicole SellersNorfolk$12K
- Amy WenzelMechanicsville$11K
- Robert GrossmanDanville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.